LinkedIn Profile

Access StemBioSys historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:stembiosys 6625749 Jun 3rd, 2019 12:00AM StemBioSys, Inc. 224 16.00 Open Biotechnology Jun 3rd, 2019 12:30PM Jun 3rd, 2019 12:30PM OVERVIEW StemBioSys is located in San Antonio, Texas and proximate to the University of Texas Health Science Center San Antonio (UTHSC-SA) from which we have licensed proprietary and disruptive technology for the enhanced isolation, growth and delivery of stem cells or other difficult to culture cells for research, diagnostic and therapeutic applications. BUSINESS We are currently focused on scale-up activities for our patented core technology, bone marrow – High Performance Microenvironment (BM-HPME™) and our initial product launch to the stem cell research market in mid-2015. Build-out of our cGMP facility with partner BioBridge Global is complete and we have begun to explore therapeutic applications and business relationships with potential partners for other, next generation, product offerings from this versatile platform technology. TECHNOLOGY Our core novel technology platform is an advanced stem cell culture system – HPME™ – High Performance MicroEnvironment. BM-HPME™ replicates the 3-dimensional “home” in which stem cells naturally reside and proliferate. Stem cells grown in BM-HPME™ remain small, proliferative and undifferentiated. Our unique technology enables users to isolate and grow stem cells and other difficult to culture cells from a variety of sources including but not limited to adipose, bone marrow and umbilical cord blood/tissue and cancer cells. MISSION Stem cells are the future of medicine. We are the future of stem cells. We will build value for our shareholders by perfecting and focusing on the use of our disruptive stem cell technology platforms, know-how and intellectual property for the treatment of meaningful medical disorders. We will establish the facilities, expertise, discipline and culture required to assure our patients, physicians, researchers and partners that everything we do will conform to the highest standards of quality. Open Biologic matrices, stem cells, cell culture, biologic product development Open 3463 Magic Drive, Suite 110 San Antonio Texas US 78229 StemBioSys Pharmaceuticals & Biotechnology
private:stembiosys 6625749 Feb 17th, 2018 12:00AM StemBioSys, Inc. 112 13.00 Open Biotechnology Feb 17th, 2018 02:25PM Feb 17th, 2018 02:25PM OVERVIEW StemBioSys is located in San Antonio, Texas and proximate to the University of Texas Health Science Center San Antonio (UTHSC-SA) from which we have licensed proprietary and disruptive technology for the enhanced isolation, growth and delivery of stem cells or other difficult to culture cells for research, diagnostic and therapeutic applications. BUSINESS We are currently focused on scale-up activities for our patented core technology, bone marrow – High Performance Microenvironment (BM-HPME™) and our initial product launch to the stem cell research market in mid-2015. Build-out of our cGMP facility with partner BioBridge Global is complete and we have begun to explore therapeutic applications and business relationships with potential partners for other, next generation, product offerings from this versatile platform technology. TECHNOLOGY Our core novel technology platform is an advanced stem cell culture system – HPME™ – High Performance MicroEnvironment. BM-HPME™ replicates the 3-dimensional “home” in which stem cells naturally reside and proliferate. Stem cells grown in BM-HPME™ remain small, proliferative and undifferentiated. Our unique technology enables users to isolate and grow stem cells and other difficult to culture cells from a variety of sources including but not limited to adipose, bone marrow and umbilical cord blood/tissue and cancer cells. MISSION Stem cells are the future of medicine. We are the future of stem cells. We will build value for our shareholders by perfecting and focusing on the use of our disruptive stem cell technology platforms, know-how and intellectual property for the treatment of meaningful medical disorders. We will establish the facilities, expertise, discipline and culture required to assure our patients, physicians, researchers and partners that everything we do will conform to the highest standards of quality. StemBioSys Pharmaceuticals & Biotechnology
private:stembiosys 6625749 Feb 16th, 2018 12:00AM StemBioSys, Inc. 112 13.00 Open Biotechnology Feb 16th, 2017 08:15AM Feb 16th, 2017 08:15AM OVERVIEW StemBioSys is located in San Antonio, Texas and proximate to the University of Texas Health Science Center San Antonio (UTHSC-SA) from which we have licensed proprietary and disruptive technology for the enhanced isolation, growth and delivery of stem cells or other difficult to culture cells for research, diagnostic and therapeutic applications. BUSINESS We are currently focused on scale-up activities for our patented core technology, bone marrow – High Performance Microenvironment (BM-HPME™) and our initial product launch to the stem cell research market in mid-2015. Build-out of our cGMP facility with partner BioBridge Global is complete and we have begun to explore therapeutic applications and business relationships with potential partners for other, next generation, product offerings from this versatile platform technology. TECHNOLOGY Our core novel technology platform is an advanced stem cell culture system – HPME™ – High Performance MicroEnvironment. BM-HPME™ replicates the 3-dimensional “home” in which stem cells naturally reside and proliferate. Stem cells grown in BM-HPME™ remain small, proliferative and undifferentiated. Our unique technology enables users to isolate and grow stem cells and other difficult to culture cells from a variety of sources including but not limited to adipose, bone marrow and umbilical cord blood/tissue and cancer cells. MISSION Stem cells are the future of medicine. We are the future of stem cells. We will build value for our shareholders by perfecting and focusing on the use of our disruptive stem cell technology platforms, know-how and intellectual property for the treatment of meaningful medical disorders. We will establish the facilities, expertise, discipline and culture required to assure our patients, physicians, researchers and partners that everything we do will conform to the highest standards of quality. StemBioSys Pharmaceuticals & Biotechnology
private:stembiosys 6625749 Feb 15th, 2018 12:00AM StemBioSys, Inc. 112 13.00 Open Biotechnology Feb 15th, 2017 10:07AM Feb 15th, 2017 10:07AM OVERVIEW StemBioSys is located in San Antonio, Texas and proximate to the University of Texas Health Science Center San Antonio (UTHSC-SA) from which we have licensed proprietary and disruptive technology for the enhanced isolation, growth and delivery of stem cells or other difficult to culture cells for research, diagnostic and therapeutic applications. BUSINESS We are currently focused on scale-up activities for our patented core technology, bone marrow – High Performance Microenvironment (BM-HPME™) and our initial product launch to the stem cell research market in mid-2015. Build-out of our cGMP facility with partner BioBridge Global is complete and we have begun to explore therapeutic applications and business relationships with potential partners for other, next generation, product offerings from this versatile platform technology. TECHNOLOGY Our core novel technology platform is an advanced stem cell culture system – HPME™ – High Performance MicroEnvironment. BM-HPME™ replicates the 3-dimensional “home” in which stem cells naturally reside and proliferate. Stem cells grown in BM-HPME™ remain small, proliferative and undifferentiated. Our unique technology enables users to isolate and grow stem cells and other difficult to culture cells from a variety of sources including but not limited to adipose, bone marrow and umbilical cord blood/tissue and cancer cells. MISSION Stem cells are the future of medicine. We are the future of stem cells. We will build value for our shareholders by perfecting and focusing on the use of our disruptive stem cell technology platforms, know-how and intellectual property for the treatment of meaningful medical disorders. We will establish the facilities, expertise, discipline and culture required to assure our patients, physicians, researchers and partners that everything we do will conform to the highest standards of quality. StemBioSys Pharmaceuticals & Biotechnology
private:stembiosys 6625749 Feb 14th, 2018 12:00AM StemBioSys, Inc. 112 13.00 Open Biotechnology Feb 14th, 2017 01:50PM Feb 14th, 2017 01:50PM OVERVIEW StemBioSys is located in San Antonio, Texas and proximate to the University of Texas Health Science Center San Antonio (UTHSC-SA) from which we have licensed proprietary and disruptive technology for the enhanced isolation, growth and delivery of stem cells or other difficult to culture cells for research, diagnostic and therapeutic applications. BUSINESS We are currently focused on scale-up activities for our patented core technology, bone marrow – High Performance Microenvironment (BM-HPME™) and our initial product launch to the stem cell research market in mid-2015. Build-out of our cGMP facility with partner BioBridge Global is complete and we have begun to explore therapeutic applications and business relationships with potential partners for other, next generation, product offerings from this versatile platform technology. TECHNOLOGY Our core novel technology platform is an advanced stem cell culture system – HPME™ – High Performance MicroEnvironment. BM-HPME™ replicates the 3-dimensional “home” in which stem cells naturally reside and proliferate. Stem cells grown in BM-HPME™ remain small, proliferative and undifferentiated. Our unique technology enables users to isolate and grow stem cells and other difficult to culture cells from a variety of sources including but not limited to adipose, bone marrow and umbilical cord blood/tissue and cancer cells. MISSION Stem cells are the future of medicine. We are the future of stem cells. We will build value for our shareholders by perfecting and focusing on the use of our disruptive stem cell technology platforms, know-how and intellectual property for the treatment of meaningful medical disorders. We will establish the facilities, expertise, discipline and culture required to assure our patients, physicians, researchers and partners that everything we do will conform to the highest standards of quality. StemBioSys Pharmaceuticals & Biotechnology
private:stembiosys 6625749 Feb 13th, 2018 12:00AM StemBioSys, Inc. 112 13.00 Open Biotechnology Feb 13th, 2017 04:11PM Feb 13th, 2017 04:11PM OVERVIEW StemBioSys is located in San Antonio, Texas and proximate to the University of Texas Health Science Center San Antonio (UTHSC-SA) from which we have licensed proprietary and disruptive technology for the enhanced isolation, growth and delivery of stem cells or other difficult to culture cells for research, diagnostic and therapeutic applications. BUSINESS We are currently focused on scale-up activities for our patented core technology, bone marrow – High Performance Microenvironment (BM-HPME™) and our initial product launch to the stem cell research market in mid-2015. Build-out of our cGMP facility with partner BioBridge Global is complete and we have begun to explore therapeutic applications and business relationships with potential partners for other, next generation, product offerings from this versatile platform technology. TECHNOLOGY Our core novel technology platform is an advanced stem cell culture system – HPME™ – High Performance MicroEnvironment. BM-HPME™ replicates the 3-dimensional “home” in which stem cells naturally reside and proliferate. Stem cells grown in BM-HPME™ remain small, proliferative and undifferentiated. Our unique technology enables users to isolate and grow stem cells and other difficult to culture cells from a variety of sources including but not limited to adipose, bone marrow and umbilical cord blood/tissue and cancer cells. MISSION Stem cells are the future of medicine. We are the future of stem cells. We will build value for our shareholders by perfecting and focusing on the use of our disruptive stem cell technology platforms, know-how and intellectual property for the treatment of meaningful medical disorders. We will establish the facilities, expertise, discipline and culture required to assure our patients, physicians, researchers and partners that everything we do will conform to the highest standards of quality. StemBioSys Pharmaceuticals & Biotechnology
private:stembiosys 6625749 Feb 12th, 2018 12:00AM StemBioSys, Inc. 112 13.00 Open Biotechnology Feb 12th, 2017 04:15AM Feb 12th, 2017 04:15AM OVERVIEW StemBioSys is located in San Antonio, Texas and proximate to the University of Texas Health Science Center San Antonio (UTHSC-SA) from which we have licensed proprietary and disruptive technology for the enhanced isolation, growth and delivery of stem cells or other difficult to culture cells for research, diagnostic and therapeutic applications. BUSINESS We are currently focused on scale-up activities for our patented core technology, bone marrow – High Performance Microenvironment (BM-HPME™) and our initial product launch to the stem cell research market in mid-2015. Build-out of our cGMP facility with partner BioBridge Global is complete and we have begun to explore therapeutic applications and business relationships with potential partners for other, next generation, product offerings from this versatile platform technology. TECHNOLOGY Our core novel technology platform is an advanced stem cell culture system – HPME™ – High Performance MicroEnvironment. BM-HPME™ replicates the 3-dimensional “home” in which stem cells naturally reside and proliferate. Stem cells grown in BM-HPME™ remain small, proliferative and undifferentiated. Our unique technology enables users to isolate and grow stem cells and other difficult to culture cells from a variety of sources including but not limited to adipose, bone marrow and umbilical cord blood/tissue and cancer cells. MISSION Stem cells are the future of medicine. We are the future of stem cells. We will build value for our shareholders by perfecting and focusing on the use of our disruptive stem cell technology platforms, know-how and intellectual property for the treatment of meaningful medical disorders. We will establish the facilities, expertise, discipline and culture required to assure our patients, physicians, researchers and partners that everything we do will conform to the highest standards of quality. StemBioSys Pharmaceuticals & Biotechnology
private:stembiosys 6625749 Feb 11th, 2018 12:00AM StemBioSys, Inc. 112 13.00 Open Biotechnology Feb 11th, 2017 05:35AM Feb 11th, 2017 05:35AM OVERVIEW StemBioSys is located in San Antonio, Texas and proximate to the University of Texas Health Science Center San Antonio (UTHSC-SA) from which we have licensed proprietary and disruptive technology for the enhanced isolation, growth and delivery of stem cells or other difficult to culture cells for research, diagnostic and therapeutic applications. BUSINESS We are currently focused on scale-up activities for our patented core technology, bone marrow – High Performance Microenvironment (BM-HPME™) and our initial product launch to the stem cell research market in mid-2015. Build-out of our cGMP facility with partner BioBridge Global is complete and we have begun to explore therapeutic applications and business relationships with potential partners for other, next generation, product offerings from this versatile platform technology. TECHNOLOGY Our core novel technology platform is an advanced stem cell culture system – HPME™ – High Performance MicroEnvironment. BM-HPME™ replicates the 3-dimensional “home” in which stem cells naturally reside and proliferate. Stem cells grown in BM-HPME™ remain small, proliferative and undifferentiated. Our unique technology enables users to isolate and grow stem cells and other difficult to culture cells from a variety of sources including but not limited to adipose, bone marrow and umbilical cord blood/tissue and cancer cells. MISSION Stem cells are the future of medicine. We are the future of stem cells. We will build value for our shareholders by perfecting and focusing on the use of our disruptive stem cell technology platforms, know-how and intellectual property for the treatment of meaningful medical disorders. We will establish the facilities, expertise, discipline and culture required to assure our patients, physicians, researchers and partners that everything we do will conform to the highest standards of quality. StemBioSys Pharmaceuticals & Biotechnology
private:stembiosys 6625749 Feb 10th, 2018 12:00AM StemBioSys, Inc. 112 13.00 Open Biotechnology Feb 10th, 2017 06:43AM Feb 10th, 2017 06:43AM OVERVIEW StemBioSys is located in San Antonio, Texas and proximate to the University of Texas Health Science Center San Antonio (UTHSC-SA) from which we have licensed proprietary and disruptive technology for the enhanced isolation, growth and delivery of stem cells or other difficult to culture cells for research, diagnostic and therapeutic applications. BUSINESS We are currently focused on scale-up activities for our patented core technology, bone marrow – High Performance Microenvironment (BM-HPME™) and our initial product launch to the stem cell research market in mid-2015. Build-out of our cGMP facility with partner BioBridge Global is complete and we have begun to explore therapeutic applications and business relationships with potential partners for other, next generation, product offerings from this versatile platform technology. TECHNOLOGY Our core novel technology platform is an advanced stem cell culture system – HPME™ – High Performance MicroEnvironment. BM-HPME™ replicates the 3-dimensional “home” in which stem cells naturally reside and proliferate. Stem cells grown in BM-HPME™ remain small, proliferative and undifferentiated. Our unique technology enables users to isolate and grow stem cells and other difficult to culture cells from a variety of sources including but not limited to adipose, bone marrow and umbilical cord blood/tissue and cancer cells. MISSION Stem cells are the future of medicine. We are the future of stem cells. We will build value for our shareholders by perfecting and focusing on the use of our disruptive stem cell technology platforms, know-how and intellectual property for the treatment of meaningful medical disorders. We will establish the facilities, expertise, discipline and culture required to assure our patients, physicians, researchers and partners that everything we do will conform to the highest standards of quality. StemBioSys Pharmaceuticals & Biotechnology
private:stembiosys 6625749 Feb 9th, 2018 12:00AM StemBioSys, Inc. 112 13.00 Open Biotechnology Feb 9th, 2017 08:57AM Feb 9th, 2017 08:57AM OVERVIEW StemBioSys is located in San Antonio, Texas and proximate to the University of Texas Health Science Center San Antonio (UTHSC-SA) from which we have licensed proprietary and disruptive technology for the enhanced isolation, growth and delivery of stem cells or other difficult to culture cells for research, diagnostic and therapeutic applications. BUSINESS We are currently focused on scale-up activities for our patented core technology, bone marrow – High Performance Microenvironment (BM-HPME™) and our initial product launch to the stem cell research market in mid-2015. Build-out of our cGMP facility with partner BioBridge Global is complete and we have begun to explore therapeutic applications and business relationships with potential partners for other, next generation, product offerings from this versatile platform technology. TECHNOLOGY Our core novel technology platform is an advanced stem cell culture system – HPME™ – High Performance MicroEnvironment. BM-HPME™ replicates the 3-dimensional “home” in which stem cells naturally reside and proliferate. Stem cells grown in BM-HPME™ remain small, proliferative and undifferentiated. Our unique technology enables users to isolate and grow stem cells and other difficult to culture cells from a variety of sources including but not limited to adipose, bone marrow and umbilical cord blood/tissue and cancer cells. MISSION Stem cells are the future of medicine. We are the future of stem cells. We will build value for our shareholders by perfecting and focusing on the use of our disruptive stem cell technology platforms, know-how and intellectual property for the treatment of meaningful medical disorders. We will establish the facilities, expertise, discipline and culture required to assure our patients, physicians, researchers and partners that everything we do will conform to the highest standards of quality. StemBioSys Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.